RESUMEN
We report a rare case of a cerebral infection with Taenia crassiceps tapeworm larvae in an immunocompetent 71-year-old German male. Initially, an intracerebral malignoma was suspected after the patient experienced stroke-like symptoms. After surgery, helminth larvae, later identified as T. crassiceps, were detected. Identification on the species level was possible by specific PCR and sequencing. After complete surgical removal, the patient was treated with albendazole and dexamethasone for two weeks. No residual symptoms were reported up to date.
Asunto(s)
Neurocisticercosis , Taenia , Animales , Masculino , Humanos , Anciano , Neurocisticercosis/diagnóstico , Larva , Albendazol/uso terapéuticoRESUMEN
BACKGROUND: Plasma Galectin-3 is a marker of myocardial inflammation and fibrosis, was associated with left ventricular (LV) reverse remodeling after conventional surgical mitral valve repair (MVR) and predicted clinical events in patients undergoing transcatheter aortic valve replacement (TAVR). We aimed to evaluate the association between pre-interventional Galectin-3 levels and (1) reverse LV remodeling and (2) major adverse cardiovascular events (MACE) in patients undergoing percutaneous MVR. METHODS: Forty-four consecutive patients (median age 79â¯years, LV ejection fraction 39.5⯱â¯11.4%, 91% in NYHA functional class ≥III) with symptomatic moderate to severe mitral regurgitation undergoing percutaneous MVR were prospectively included. Plasma Galectin-3 levels were measured before the procedure. Echocardiographic and clinical assessment was performed at baseline and after 3â¯months. LV reverse remodeling was prospectively defined as a ≥10% increase in global longitudinal strain. MACE included death, myocardial infarction, heart failure related rehospitalization and stroke and was assessed after a mean follow-up time of 2â¯years. RESULTS: 72.7% of the patients showed LV reverse remodeling. Pre-interventional Galectin-3â¯<â¯10â¯ng/ml was an independent predictor of LV reverse remodeling (OR 10.3, 95% CI 1.2-83.9, pâ¯=â¯0.036). 25 patients (56.8%) experienced a MACE. Patients with Galectin-3 levelsâ¯≥â¯10â¯ng/ml had significantly more MACE than patients with Galectin-3 levelsâ¯<â¯10â¯ng/ml (100% vs. 45.5%, pâ¯=â¯0.003). Diabetes independently predicted MACE (HR 3.1, 95% CI 1.0-9.4, pâ¯=â¯0.049); Galectin-3â¯≥â¯10â¯ng/ml was of borderline significance (HR 2.2, 95% CI 0.9-5.4, pâ¯=â¯0.088). CONCLUSIONS: Pre-interventional plasma Galectin-3 levels are associated with LV reverse remodeling and with clinical outcome after percutaneous MVR.